Skip to main content
. Author manuscript; available in PMC: 2021 Dec 16.
Published in final edited form as: Sci Transl Med. 2020 Dec 16;12(574):eaax3519. doi: 10.1126/scitranslmed.aax3519

Figure 4. Loss of Chi3l1 mitigates astrogliosis, but facilitates phagocytosis in the presence of Aβ.

Figure 4.

A. Representative high magnification images from hippocampi of 8 mo Chi3l1−/−:APP/PS1+ and APP/PS1+ control mice stained for X34 (fibrillar plaques) and GFAP (astrocytes). Scale bar = 20μm

B–C. Quantification of GFAP coverage (B) or GFAP coverage normalized to X34+ area in same section (C) from mice in (A). Quantified from widefield image in Fig. S5. RS = retrosplenial. n = 6 (Chi3l1+/+) and 12 (Chi3l1−/−:) mice per group.

D. Astrocyte activation marker gene expression from fluidigm qPCR of 8 mo Chi3l1−/−:APP/PS1−, WT:APP/PS1−, Chi3l1−/−:APP/PS1+, and APP/PS1+ control mouse hippocampus. Mean of 4 mice (APP/PS1−) or 6–10 (APP/PS1+) mice per group normalized to WT:APP/PS1−. Two-way ANOVA with Tukey correction for multiple comparisons.

E–F. pHrodo-labeled zymosan bead (E) or TAMRA-Aβ (F) uptake by primary astrocyte cultures transfected with control (siSCR) or Chi3l1 (siChi3l1) siRNA, +/− cytochalasin D to inhibit phagocytosis (+cytoD). Each point represents one field of view with an average of 804 (E) or 517 (F) cells/field. Data from 2 independent experiments.

All data represent mean +/− SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Analyzed by two-tailed students t-test (B–C) or one-way ANOVA (E-F). All data subjected to Sidak correction for multiple comparisons unless otherwise noted.